Melinda Gooderham, MSc, MD, FRCPC: JAK Inhibitors for Psoriasis
Dr. Gooderham discusses JAK inhibition in the context of psoriasis treatment, including comparing the important difference between competitive inhibition and allosteric inhibition when using JAKs to treat psoriasis.
Raj Chovatiya, MD, PhD: Social and Structural Disease-State Disparities in Inflammatory Skin Disease in Skin of Color
Dr. Chovatiya reviews one of his AAD sessions in which he discussed atopic dermatitis, hidradenitis suppurativa, and psoriasis in patients with skin of color. In these highlights from his expansive talk, Dr. Chovatiya notes that while the manifestations of these diseases are not biologically distinct between patients of different races, there are many social and […]
Aaron Drucker MD, SCM, FRCPC: A Network Meta-analysis of Systemic Therapies for Atopic Dermatitis
In a summary of one of his talks from AAD 2025, Dr. Drucker discusses the results from a network meta-analysis that provides insight beyond the primary literature regarding the efficacy of systemic therapies for AD, including oral JAK inhibitors and biologics.
Diego Ruiz Dasilva, MD, FAAD: Achievement of Optimal Treatment Targets with Oral JAK Inhibition in Elderly Patients with Atopic Dermatitis
Dr. Dasilva discusses positive results from a recent study published in the Journal of Clinical and Aesthetic Dermatology that assessed the safety and efficacy of JAK inhibitors in a group of elderly patients. Click here to read the full article. Reference:
Jennifer Silva, APRN-DNP: Providing Adequate Treatment for Patients with Vitiligo
Jennifer Silva discusses a few treatment strategies to utilize in patients who continue to struggle to find effective treatment for their vitiligo.